系统性风湿性疾病CAR-T免疫疗法临床研究进展

doi:10.12092/j.issn.1009-2501.2024.08.011

中国临床药理学与治疗学 ›› 2024, Vol. 29 ›› Issue (8): 937-946.doi: 10.12092/j.issn.1009-2501.2024.08.011

系统性风湿性疾病CAR-T免疫疗法临床研究进展

李志1，张梦莹2，朱传苗1，毛丽1，彭辉3

1皖南医学院第一附属医院风湿免疫科；2中心实验室；3科技处，芜湖 241000，安徽

收稿日期:2024-03-08 修回日期:2024-03-20 出版日期:2024-08-26 发布日期:2024-07-17
通讯作者: 彭辉，男，硕士，副研究员，副教授，研究方向：流行病学。 E-mail: phui.1234@163.com
作者简介:李志，男，硕士，副主任医师，副教授，研究方向：自身免疫性疾病发病机制与治疗。 E-mail: zhili-8848@qq.com
基金资助:
安徽省自然科学基金项目（1808085QH251）

Advances in clinical research of CAR-T immunotherapy for systemic rheumatic diseases

LI Zhi1, ZHANG Mengying2, ZHU Chuanmiao1, MAO Li1, PENG Hui3

1 Department of Rheumatology, 2 Central Laboratory, 3 Office of science and technology administration, The First Affiliated Hospital of Wannan Medical College, Wuhu 241001, Anhui, China

Received:2024-03-08 Revised:2024-03-20 Online:2024-08-26 Published:2024-07-17

摘要/Abstract

摘要：

系统性风湿性疾病是以自身免疫细胞功能紊乱继而产生多系统多器官损害的一类自身免疫性疾病。传统免疫抑制剂在系统性风湿性疾病治疗中占有重要地位，而临床中仍有相当数量的难治性系统性风湿性疾病对传统免疫抑制剂治疗反应不佳，需要探索新的治疗手段。嵌合抗原受体T细胞（chimeric antigen receptor T cell therapy，CAR-T）免疫疗法起始于恶性血液系统疾病治疗，并展现出了良好的疗效，近期CAR-T免疫疗法在难治性系统性红斑狼疮中取得了显著疗效，从而为系统性风湿性疾病的治疗带来新的希望。本文就近年来CAR-T免疫疗法在系统性风湿性疾病临床研究进展进行总结，旨在增强临床医师对CAR-T免疫疗法的认知并推动CAR-T免疫疗法在系统性风湿性疾病中进一步开展。

关键词: CAR-T, 风湿性疾病, 系统性红斑狼疮, 干燥综合征

Abstract:

Systemic rheumatic disease is a kind of autoimmune disease which is caused by the dysfunction of autoimmune cells and the damage of multiple systems and organs. Traditional immunosuppressants play an important role in the treatment of systemic rheumatic diseases, but there are still a considerable number of refractory systemic rheumatic diseases that do not respond well to traditional immunosuppressant therapy, and new therapeutic methods need to be explored. Chimeric antigen receptor T cell therapy (CAR-T) immunotherapy was initially used for the treatment of malignant hematological diseases and has shown good efficacy. Recently,CAR-T immunotherapy has also achieved remarkable efficacy in refractory systemic lupus erythematosus. It brings new hope for the treatment of systemic rheumatic diseases. This article summarizes the progress of clinical application of CAR-T immunotherapy in systemic rheumatic diseases in recent years, aiming to enhance clinicians' cognition of CAR-T immunotherapy and promote the further development of CAR-T immunotherapy in systemic rheumatic diseases.

Key words: CAR-T, rheumatic disease, systemic lupus erythematosus, sjogren syndrome

中图分类号:

R593.2

李志, 张梦莹, 朱传苗, 毛丽, 彭辉. 系统性风湿性疾病CAR-T免疫疗法临床研究进展[J]. 中国临床药理学与治疗学, 2024, 29(8): 937-946.

LI Zhi, ZHANG Mengying, ZHU Chuanmiao, MAO Li, PENG Hui. Advances in clinical research of CAR-T immunotherapy for systemic rheumatic diseases[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(8): 937-946.

[1]	张凌霄, 李婷, 许羚, 李禄金, 郑青山. 贝利木单抗治疗系统性红斑狼疮的模型化疗效评价[J]. 中国临床药理学与治疗学, 2021, 26(2): 174-181.
[2]	李桂女, 任少琳, 沈瑞明, 季永能, 蔡彩荣, 苏若. 二甲双胍联合糖皮质激素治疗伴糖耐量异常的系统性红斑狼疮患者的临床研究[J]. 中国临床药理学与治疗学, 2020, 25(6): 670-676.
[3]	陈薪薪，陈朝生. 长链非编码RNA与系统性红斑狼疮的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(4): 471-476.
[4]	孙宝，张伟. DNA甲基化在自身免疫性疾病发病机制中作用研究进展[J]. 中国临床药理学与治疗学, 2015, 20(11): 1308-1314.
[5]	张梦莹, 李志, 吕坤, 钟民, 所起凤, 钟正灵. 系统性红斑狼疮患者血清抗内皮细胞抗体和抗β₂糖蛋白I抗体水平及其对人脐静脉内皮细胞增殖的影响[J]. 中国临床药理学与治疗学, 2013, 18(2): 142-146.
[6]	赵海慧, 赵阴环. T细胞异常活化在系统性红斑狼疮中的分子免疫机制[J]. 中国临床药理学与治疗学, 2012, 17(4): 452-457.
[7]	梁卫, 金琳, 龚林, 张丽玲, 廖晖, 蔡鹰, 唐永明. 清热化瘀滋阴方对系统性红斑狼疮外周血淋巴细胞凋亡及Fas、FasL基因表达的影响[J]. 中国临床药理学与治疗学, 2009, 14(9): 1056-1060.
[8]	袁国龙, 徐亮, 李志, 陈兰芳, 宣丹, 陆进明. 去除IgG的系统性红斑狼疮血小板减少血清对脐带血巨核细胞克隆形成单位生成的影响[J]. 中国临床药理学与治疗学, 2008, 13(10): 1163-1167.

系统性风湿性疾病CAR-T免疫疗法临床研究进展

Advances in clinical research of CAR-T immunotherapy for systemic rheumatic diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 8

编辑推荐

Metrics

本文评价